drugset / Trial / NCT03645200
Treatment of Carrying TP53 Harmful Mutations
Phase 1
Unknown
60 enrolled
Tianjin Medical University Second Hospital
Jiangsu HengRui Medicine Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
Assessment of the safety and tolerability of Fluzoparib combined with Apatinib in the treatment of advanced refractory solid tumors with TP53 harmful mutations.
Timeline
- Start
- 2019-07-01
- Primary completion
- 2019-12-01
- Completion
- 2020-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fluzoparib | Small molecule | 40 mg | Oral |
| Subject | Fluzoparib | Small molecule | 60 mg | Oral |
| Subject | Fluzoparib | Small molecule | 80 mg | Oral |
| Subject | Fluzoparib | Small molecule | 100 mg | Oral |
| Subject | Rivoceranib | Small molecule | 250 mg | — |
| Subject | Rivoceranib | Small molecule | 500 mg | — |